Does the media refer more to HROW or VNDA?

In the previous week, Vanda Pharmaceuticals had 4 more articles in the media than Harrow. MarketBeat recorded 11 mentions for Vanda Pharmaceuticals and 7 mentions for Harrow. Vanda Pharmaceuticals' average media sentiment score of 0.46 beat Harrow's score of 0.44 indicating that Vanda Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Harrow 2 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Vanda Pharmaceuticals 4 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media refer more to CRON or VNDA?

In the previous week, Vanda Pharmaceuticals had 8 more articles in the media than Cronos Group. MarketBeat recorded 11 mentions for Vanda Pharmaceuticals and 3 mentions for Cronos Group. Cronos Group's average media sentiment score of 0.86 beat Vanda Pharmaceuticals' score of 0.46 indicating that Cronos Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cronos Group 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vanda Pharmaceuticals 4 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Do analysts rate CALT or VNDA?

Vanda Pharmaceuticals has a consensus target price of $13.08, indicating a potential upside of 179.74%. Given Vanda Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Vanda Pharmaceuticals is more favorable than Calliditas Therapeutics AB (publ). Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Calliditas Therapeutics AB (publ) 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Vanda Pharmaceuticals 1 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.56

Does the media prefer ANRO or VNDA?

In the previous week, Vanda Pharmaceuticals had 6 more articles in the media than Alto Neuroscience. MarketBeat recorded 11 mentions for Vanda Pharmaceuticals and 5 mentions for Alto Neuroscience. Vanda Pharmaceuticals' average media sentiment score of 0.46 beat Alto Neuroscience's score of 0.29 indicating that Vanda Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alto Neuroscience 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Vanda Pharmaceuticals 4 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media prefer VNDA or SPTX?

In the previous week, Vanda Pharmaceuticals had 1 more articles in the media than Seaport Therapeutics. MarketBeat recorded 11 mentions for Vanda Pharmaceuticals and 10 mentions for Seaport Therapeutics. Seaport Therapeutics' average media sentiment score of 0.77 beat Vanda Pharmaceuticals' score of 0.46 indicating that Seaport Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vanda Pharmaceuticals 4 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Seaport Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Vanda Pharmaceuticals (VNDA) Competitors

$4.63 -0.18 (-3.74%)

Closing price 04:00 PM Eastern

Extended Trading

$4.58 -0.05 (-1.08%)

As of 07:47 PM Eastern

Compare

VNDA vs. HROW, CRON, CALT, ANRO, and SPTX

Should you buy Vanda Pharmaceuticals stock or one of its competitors? Vanda Pharmaceuticals's main competitors and comparable companies include Harrow (HROW), Cronos Group (CRON), Calliditas Therapeutics AB (publ) (CALT), Alto Neuroscience (ANRO), and Seaport Therapeutics (SPTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Vanda Pharmaceuticals compare to Harrow?

Harrow (NASDAQ:HROW) and Vanda Pharmaceuticals (NASDAQ:VNDA) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, media sentiment, dividends, risk, valuation, profitability and institutional ownership.

Harrow has a net margin of -13.51% compared to Vanda Pharmaceuticals' net margin of -127.41%. Harrow's return on equity of -38.00% beat Vanda Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Harrow	-13.51%	-38.00%	-3.37%
Vanda Pharmaceuticals	-127.41%	-49.81%	-33.29%

In the previous week, Vanda Pharmaceuticals had 4 more articles in the media than Harrow. MarketBeat recorded 11 mentions for Vanda Pharmaceuticals and 7 mentions for Harrow. Vanda Pharmaceuticals' average media sentiment score of 0.46 beat Harrow's score of 0.44 indicating that Vanda Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Harrow	2 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Vanda Pharmaceuticals	4 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

72.8% of Harrow shares are held by institutional investors. Comparatively, 88.1% of Vanda Pharmaceuticals shares are held by institutional investors. 12.8% of Harrow shares are held by company insiders. Comparatively, 10.7% of Vanda Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Harrow has higher revenue and earnings than Vanda Pharmaceuticals. Harrow is trading at a lower price-to-earnings ratio than Vanda Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Harrow	$272.30M	4.20	-$5.14M	-$1.00	N/A
Vanda Pharmaceuticals	$216.10M	1.31	-$220.47M	-$4.63	N/A

Harrow has a beta of 0.19, suggesting that its stock price is 81% less volatile than the broader market. Comparatively, Vanda Pharmaceuticals has a beta of 0.69, suggesting that its stock price is 31% less volatile than the broader market.

Harrow currently has a consensus price target of $66.17, indicating a potential upside of 116.87%. Vanda Pharmaceuticals has a consensus price target of $13.08, indicating a potential upside of 179.74%. Given Vanda Pharmaceuticals' higher probable upside, analysts clearly believe Vanda Pharmaceuticals is more favorable than Harrow.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Harrow	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60
Vanda Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56

Summary

Harrow beats Vanda Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

How does Vanda Pharmaceuticals compare to Cronos Group?

Cronos Group (NASDAQ:CRON) and Vanda Pharmaceuticals (NASDAQ:VNDA) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, earnings, risk, profitability, media sentiment, valuation and dividends.

In the previous week, Vanda Pharmaceuticals had 8 more articles in the media than Cronos Group. MarketBeat recorded 11 mentions for Vanda Pharmaceuticals and 3 mentions for Cronos Group. Cronos Group's average media sentiment score of 0.86 beat Vanda Pharmaceuticals' score of 0.46 indicating that Cronos Group is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cronos Group	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vanda Pharmaceuticals	4 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Cronos Group has a net margin of 39.08% compared to Vanda Pharmaceuticals' net margin of -127.41%. Cronos Group's return on equity of 4.85% beat Vanda Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cronos Group	39.08%	4.85%	4.62%
Vanda Pharmaceuticals	-127.41%	-49.81%	-33.29%

Cronos Group has higher earnings, but lower revenue than Vanda Pharmaceuticals. Vanda Pharmaceuticals is trading at a lower price-to-earnings ratio than Cronos Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cronos Group	$146.59M	8.08	-$9.45M	$0.20	16.08
Vanda Pharmaceuticals	$216.10M	1.31	-$220.47M	-$4.63	N/A

Cronos Group has a beta of 0.9, indicating that its stock price is 10% less volatile than the broader market. Comparatively, Vanda Pharmaceuticals has a beta of 0.69, indicating that its stock price is 31% less volatile than the broader market.

Cronos Group presently has a consensus target price of $2.30, indicating a potential downside of 28.46%. Vanda Pharmaceuticals has a consensus target price of $13.08, indicating a potential upside of 179.74%. Given Vanda Pharmaceuticals' higher probable upside, analysts plainly believe Vanda Pharmaceuticals is more favorable than Cronos Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cronos Group	0 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.60
Vanda Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56

8.7% of Cronos Group shares are owned by institutional investors. Comparatively, 88.1% of Vanda Pharmaceuticals shares are owned by institutional investors. 7.8% of Cronos Group shares are owned by insiders. Comparatively, 10.7% of Vanda Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Cronos Group beats Vanda Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

How does Vanda Pharmaceuticals compare to Calliditas Therapeutics AB (publ)?

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) and Vanda Pharmaceuticals (NASDAQ:VNDA) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, earnings, risk, dividends, media sentiment, valuation, analyst recommendations and profitability.

2.8% of Calliditas Therapeutics AB (publ) shares are held by institutional investors. Comparatively, 88.1% of Vanda Pharmaceuticals shares are held by institutional investors. 2.2% of Calliditas Therapeutics AB (publ) shares are held by insiders. Comparatively, 10.7% of Vanda Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Calliditas Therapeutics AB (publ) has higher revenue and earnings than Vanda Pharmaceuticals. Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than Vanda Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Calliditas Therapeutics AB (publ)	$1.60B	0.74	-$43.96M	-$1.85	N/A
Vanda Pharmaceuticals	$216.10M	1.31	-$220.47M	-$4.63	N/A

In the previous week, Vanda Pharmaceuticals had 11 more articles in the media than Calliditas Therapeutics AB (publ). MarketBeat recorded 11 mentions for Vanda Pharmaceuticals and 0 mentions for Calliditas Therapeutics AB (publ). Vanda Pharmaceuticals' average media sentiment score of 0.46 beat Calliditas Therapeutics AB (publ)'s score of 0.00 indicating that Vanda Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Calliditas Therapeutics AB (publ)	Neutral
Vanda Pharmaceuticals	Neutral

Calliditas Therapeutics AB (publ) has a net margin of -30.18% compared to Vanda Pharmaceuticals' net margin of -127.41%. Vanda Pharmaceuticals' return on equity of -49.81% beat Calliditas Therapeutics AB (publ)'s return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Calliditas Therapeutics AB (publ)	-30.18%	-212.04%	-27.96%
Vanda Pharmaceuticals	-127.41%	-49.81%	-33.29%

Vanda Pharmaceuticals has a consensus target price of $13.08, indicating a potential upside of 179.74%. Given Vanda Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Vanda Pharmaceuticals is more favorable than Calliditas Therapeutics AB (publ).

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Calliditas Therapeutics AB (publ)	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Vanda Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56

Calliditas Therapeutics AB (publ) has a beta of 1.77, suggesting that its stock price is 77% more volatile than the broader market. Comparatively, Vanda Pharmaceuticals has a beta of 0.69, suggesting that its stock price is 31% less volatile than the broader market.

Summary

Vanda Pharmaceuticals beats Calliditas Therapeutics AB (publ) on 10 of the 16 factors compared between the two stocks.

How does Vanda Pharmaceuticals compare to Alto Neuroscience?

Alto Neuroscience (NYSE:ANRO) and Vanda Pharmaceuticals (NASDAQ:VNDA) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, valuation, institutional ownership, earnings, profitability, risk, analyst recommendations and dividends.

88.1% of Vanda Pharmaceuticals shares are owned by institutional investors. 11.3% of Alto Neuroscience shares are owned by insiders. Comparatively, 10.7% of Vanda Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Alto Neuroscience has a beta of 1.32, indicating that its stock price is 32% more volatile than the broader market. Comparatively, Vanda Pharmaceuticals has a beta of 0.69, indicating that its stock price is 31% less volatile than the broader market.

Alto Neuroscience presently has a consensus price target of $37.25, indicating a potential upside of 51.39%. Vanda Pharmaceuticals has a consensus price target of $13.08, indicating a potential upside of 179.74%. Given Vanda Pharmaceuticals' higher possible upside, analysts clearly believe Vanda Pharmaceuticals is more favorable than Alto Neuroscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alto Neuroscience	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64
Vanda Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56

In the previous week, Vanda Pharmaceuticals had 6 more articles in the media than Alto Neuroscience. MarketBeat recorded 11 mentions for Vanda Pharmaceuticals and 5 mentions for Alto Neuroscience. Vanda Pharmaceuticals' average media sentiment score of 0.46 beat Alto Neuroscience's score of 0.29 indicating that Vanda Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alto Neuroscience	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Vanda Pharmaceuticals	4 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Alto Neuroscience has a net margin of 0.00% compared to Vanda Pharmaceuticals' net margin of -127.41%. Alto Neuroscience's return on equity of -46.46% beat Vanda Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alto Neuroscience	N/A	-46.46%	-39.09%
Vanda Pharmaceuticals	-127.41%	-49.81%	-33.29%

Alto Neuroscience has higher earnings, but lower revenue than Vanda Pharmaceuticals. Alto Neuroscience is trading at a lower price-to-earnings ratio than Vanda Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alto Neuroscience	N/A	N/A	-$63.24M	-$2.42	N/A
Vanda Pharmaceuticals	$216.10M	1.31	-$220.47M	-$4.63	N/A

Summary

Alto Neuroscience beats Vanda Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does Vanda Pharmaceuticals compare to Seaport Therapeutics?

Vanda Pharmaceuticals (NASDAQ:VNDA) and Seaport Therapeutics (NASDAQ:SPTX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, earnings, profitability, media sentiment, analyst recommendations, risk and institutional ownership.

Seaport Therapeutics has lower revenue, but higher earnings than Vanda Pharmaceuticals. Seaport Therapeutics is trading at a lower price-to-earnings ratio than Vanda Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vanda Pharmaceuticals	$216.10M	1.31	-$220.47M	-$4.63	N/A
Seaport Therapeutics	N/A	N/A	-$74.88M	-$12.12	N/A

In the previous week, Vanda Pharmaceuticals had 1 more articles in the media than Seaport Therapeutics. MarketBeat recorded 11 mentions for Vanda Pharmaceuticals and 10 mentions for Seaport Therapeutics. Seaport Therapeutics' average media sentiment score of 0.77 beat Vanda Pharmaceuticals' score of 0.46 indicating that Seaport Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vanda Pharmaceuticals	4 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Seaport Therapeutics	5 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Seaport Therapeutics has a net margin of 0.00% compared to Vanda Pharmaceuticals' net margin of -127.41%. Seaport Therapeutics' return on equity of 0.00% beat Vanda Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vanda Pharmaceuticals	-127.41%	-49.81%	-33.29%
Seaport Therapeutics	N/A	N/A	N/A

88.1% of Vanda Pharmaceuticals shares are held by institutional investors. 10.7% of Vanda Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Vanda Pharmaceuticals currently has a consensus price target of $13.08, indicating a potential upside of 179.74%. Seaport Therapeutics has a consensus price target of $38.57, indicating a potential upside of 114.29%. Given Vanda Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts plainly believe Vanda Pharmaceuticals is more favorable than Seaport Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vanda Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56
Seaport Therapeutics	2 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.50

Summary

Vanda Pharmaceuticals beats Seaport Therapeutics on 8 of the 14 factors compared between the two stocks.

Get Vanda Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VNDA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VNDA vs. The Competition

Export

Metric	Vanda Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$290.83M	$12.18B	$7.09B	$13.24B
Dividend Yield	N/A	2.63%	2.53%	15.89%
P/E Ratio	-1.00	797.15	274.61	26.05
Price / Sales	1.30	751.64	600.51	90.03
Price / Cash	N/A	81.79	77.38	51.25
Price / Book	0.84	10.47	10.92	6.31
Net Income	-$220.47M	$2.83B	$3.50B	$361.43M
7 Day Performance	-8.32%	-1.65%	-2.11%	-1.67%
1 Month Performance	-16.27%	-5.77%	-6.34%	-3.94%
1 Year Performance	-10.27%	-3.80%	8.81%	2.77%

Vanda Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VNDA Vanda Pharmaceuticals	2.7703 of 5 stars	$4.63 -3.7%	$13.08 +182.6%	-5.7%	$290.83M	$216.10M	N/A	533	News Coverage Gap Up
HROW Harrow	2.2624 of 5 stars	$33.92 +2.5%	$66.38 +95.7%	-36.7%	$1.24B	$272.30M	N/A	373
CRON Cronos Group	1.3606 of 5 stars	$3.33 -0.6%	$2.30 -30.9%	+20.7%	$1.23B	$146.59M	30.45	610
CALT Calliditas Therapeutics AB (publ)	N/A	$40.00 flat	N/A	N/A	$1.19B	$1.60B	N/A	180
ANRO Alto Neuroscience	2.3025 of 5 stars	$30.73 +1.5%	$37.25 +21.2%	+516.5%	$1.19B	N/A	N/A	68	News Coverage Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VNDA) was last updated on 10/2/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Vanda Pharmaceuticals (VNDA) Competitors

VNDA vs. HROW, CRON, CALT, ANRO, and SPTX

How does Vanda Pharmaceuticals compare to Harrow?

Summary

How does Vanda Pharmaceuticals compare to Cronos Group?

Summary

How does Vanda Pharmaceuticals compare to Calliditas Therapeutics AB (publ)?

Summary

How does Vanda Pharmaceuticals compare to Alto Neuroscience?

Summary

How does Vanda Pharmaceuticals compare to Seaport Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VNDA vs. The Competition

Vanda Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Vanda Pharmaceuticals (VNDA) Competitors

VNDA vs. HROW, CRON, CALT, ANRO, and SPTX

How does Vanda Pharmaceuticals compare to Harrow?

Is HROW or VNDA more profitable?

Does the media refer more to HROW or VNDA?

Do institutionals and insiders have more ownership in HROW or VNDA?

Which has stronger earnings and valuation, HROW or VNDA?

Which has more volatility and risk, HROW or VNDA?

Do analysts recommend HROW or VNDA?

Summary

How does Vanda Pharmaceuticals compare to Cronos Group?

Does the media refer more to CRON or VNDA?

Is CRON or VNDA more profitable?

Which has better earnings & valuation, CRON or VNDA?

Which has more risk & volatility, CRON or VNDA?

Do analysts prefer CRON or VNDA?

Do institutionals & insiders believe in CRON or VNDA?

Summary

How does Vanda Pharmaceuticals compare to Calliditas Therapeutics AB (publ)?

Do insiders & institutionals have more ownership in CALT or VNDA?

Which has higher valuation & earnings, CALT or VNDA?

Does the media prefer CALT or VNDA?

Is CALT or VNDA more profitable?

Do analysts rate CALT or VNDA?

Which has more volatility and risk, CALT or VNDA?

Summary

How does Vanda Pharmaceuticals compare to Alto Neuroscience?

Do insiders and institutionals believe in ANRO or VNDA?

Which has more volatility & risk, ANRO or VNDA?

Do analysts recommend ANRO or VNDA?

Does the media prefer ANRO or VNDA?

Is ANRO or VNDA more profitable?

Which has better valuation & earnings, ANRO or VNDA?

Summary

How does Vanda Pharmaceuticals compare to Seaport Therapeutics?

Which has better earnings & valuation, VNDA or SPTX?

Does the media prefer VNDA or SPTX?

Is VNDA or SPTX more profitable?

Do institutionals and insiders have more ownership in VNDA or SPTX?

Do analysts recommend VNDA or SPTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VNDA vs. The Competition

Vanda Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools